期刊文献+
共找到84篇文章
< 1 2 5 >
每页显示 20 50 100
REGULAR EXPRESSION OF DISCOIDIN DOMAIN RECEPTOR 2 IN THE IMPROVED ADJUVANT-INDUCED ANIMAL MODEL FOR RHEUMATOID ARTHRITIS 被引量:1
1
作者 WeiLi Yuan-qiangZhang +2 位作者 Xin-pingLiu Li-boYao LanSun 《Chinese Medical Sciences Journal》 CAS CSCD 2005年第2期133-137, ,共5页
Objective To investigate the expression of discoidin domain receptor 2 (DDR2) of fibroblast-like synovial cells in im- proved adjuvant-induced animal (AIA) model for rheumatoid arthritis (RA) and to provide evidence f... Objective To investigate the expression of discoidin domain receptor 2 (DDR2) of fibroblast-like synovial cells in im- proved adjuvant-induced animal (AIA) model for rheumatoid arthritis (RA) and to provide evidence for DDR2’s antagonist use clinically. Methods AIA was modified by administrating 0.1 mL of complete Freund’s adjuvant (CFA, mixed with 5 mg Bacillus Calmette-Guerin vaccine/mL) into rats’ right hind paws and 0.125 mL tumor necrosis factor-α (2 U/mL) into right ankles and subpatellar fatty tissue. The expression of DDR2 in fibroblast-like synovial cells was assessed using immunohistochemistry, immunofluorescence histochemistry, and in situ hybridization methods. Levels of anti-collagen II antibody were measured using enzyme-linked immunosorbent assay. Results Given the terms mentioned above, we found a more practical rat model, apparently decreasing immunization time (average 3-5 days). DDR2 can be detected upon the 15th day of immunization; expression gradually increased with time going on, and reaching a peak 35 days after immunization before gradually decreasing. Serum anti-collagen II antibody showed similar expression patterns as DDR2, but reached peak later than DDR2, about 40 days after immunization. Conclusion Regular expression of DDR2 in animal models infers its important role in the pathological process of RA. 展开更多
关键词 rheumatoid arthritis adjuvant-induced arthritis discoidin domain receptor 2 synovial tissue anti-collagen antibody
下载PDF
Tumor specifically internalizing peptide ‘HN-1’: Targeting the putative receptor retinoblastoma-regulated discoidin domain receptor 1 involved in metastasis
2
作者 Frank-Un Hong Miguel Castro Klaus Linse 《World Journal of Clinical Oncology》 CAS 2022年第5期323-338,共16页
BACKGROUND Less than 0.5%of intravenously injected drugs reach tumors,contributing to side effects.To limit damage to healthy cells,various delivery vectors have been formulated;yet,previously developed vectors suffer... BACKGROUND Less than 0.5%of intravenously injected drugs reach tumors,contributing to side effects.To limit damage to healthy cells,various delivery vectors have been formulated;yet,previously developed vectors suffer from poor penetration into solid tumors.This issue was resolved by the discovery of HN-1 peptide isolated via biopanning a phage-display library.HN-1 targets human head and neck squamous cell carcinoma(HNSCC)(breast,thyroid;potentially lung,cervix,uterine,colon cancer),translocates across the cell membrane,and efficiently infiltrates solid tumors.HN-1 peptide has been conjugated to various anticancer drugs and imaging agents though the identity of its receptor remained enigmatic.AIM To decipher the clues that pointed to retinoblastoma(Rb)-regulated discoidindomain receptor 1 as the putative receptor for HN-1 is described.METHODS HN-1 peptide was synthesized and purified using reverse-phase highperformance liquid chromatography and gel electrophoresis.The predicted mass was confirmed by mass spectroscopy.To image the 3-dimensional structure of HN-1 peptide,PyMOL was used.Molecular modeling was also performed with PEP-FOLD3 software via RPBS bioinformatics web portal(INSERM,France).The immunohistochemistry results of discoidin domain receptor 1(DDR1)protein were obtained from the publicly accessible database in the Human Protein Atlas portal,which contained the images of immunohistochemically labeled human cancers and the corresponding normal tissues.RESULTS The clues that led to DDR1 involved in metastasis as the putative receptor mediating HN-1 endocytosis are the following:(1)HN-1 is internalized in phosphate-buffered saline and its uptake is competitively inhibited;(2)HN-1(TSPLNIHNGQKL)exhibits similarity with a stretch of amino acids in alpha5 beta3 integrin(KLLITIHDRKEF).Aside from two identical residues(Ile-His)in the middle,the overall distribution of polar and nonpolar residues throughout the sequences is nearly identical.As HN-1 sequence lacks the Arg-Gly-Asp motif recognized by integrins,HN-1 may interact with an"integrin-like"molecule.The tertiary structure of both peptides showed similarity at the 3-dimensional level;(3)HN-1 is internalized by attached cells but not by suspended cells.As culture plates are typically coated with collagen,collagen-binding receptor(expressed by adherent but not suspended cells)may represent the receptor for HN-1;(4)DDR1 is highly expressed in head and neck cancer(or breast cancer)targeted by HN-1;(5)Upon activation by collagen,DDR1 becomes internalized and compartmentalized in endosomes consistent with the determination of’energy-dependent clathrin-mediated endocytosis’as the HN-1 entry route and the identification of HN-1 entrapped vesicles as endosomes;and(6)DDR1 is essential for the development of mammary glands consistent with the common embryonic lineage rationale used to identify breast cancer as an additional target of HN-1.In summary,collagenactivated tyrosine kinase receptor DDR1 overexpressed in HNSCC assumes a critical role in metastasis.Further studies are warranted to assess HN-1 peptide’s interaction with DDR1 and the therapeutic potential of treating metastatic cancer.Additionally,advances in delivery(conformation,endocytic mechanism,repertoire of targeted cancers of HN-1 peptide),tracking(HN-1 conjugated imaging agents),and activity(HN-1 conjugated therapeutic agents)are described.CONCLUSION The discovery of DDR1 as HN-1 peptide’s putative receptor represents a significant advance as it enables identification of metastatic cancers or clinical application of previously developed therapeutics to block metastasis. 展开更多
关键词 HN-1 peptide Solid tumor Targeted drug delivery discoidin domain receptor 1 Tyrosine kinase METASTASIS
下载PDF
Discoidin domain receptor 1 as a potent therapeutic target in solid tumors
3
作者 Shaheen Bibi Weihong Zeng +2 位作者 Peiyi Zheng Seyed Majid Mousavi Mehmandousti Tengchuan Jin 《hLife》 2024年第9期454-466,共13页
Despite significant discoveries in basic cancer research and improvements in treatment options and clinical outcomes,cancer remains a major public health concern worldwide.Today,the main focus of cancer research is the... Despite significant discoveries in basic cancer research and improvements in treatment options and clinical outcomes,cancer remains a major public health concern worldwide.Today,the main focus of cancer research is the signaling pathways that are crucial for cell survival,cell proliferation,and cell migration.The aberrant expression of proteins involved in these signaling pathways often leads to abnormal cell growth,cell metastasis,and invasion of healthy tis-sues.One such protein is discoidin domain receptor 1(DDR1)which belongs to the family of receptor tyrosine kinases(RTKs)and is activated upon collagen binding,as a result,downstream signaling pathways are stimulated which are responsible for cell survival,cell growth,adhesion,extracellular matrix remodeling,and cell migration.DDR1 is found to have abnormally elevated expression in various solid tumors,implying a critical role in cancer progression.Tradi-tional cancer treatment involves the use of cytotoxic drugs,chemotherapy,radiotherapy,and surgery,which do not pro-vide long-term survival and often result in cancer recurrence.Numerous small-molecule kinase inhibitors have been synthesized against RTKs including DDR1 and have been highly efficacious in tumor reduction.More recently,targeting the DDR1 extracellular domain(ECD)has garnered much attention from researchers,as inhibiting the DDR1-collagen binding has been attributed to maximizing the likelihood of the combined cytotoxic effect of both immune cells and tar-geted drugs.This review focuses on the structure,function,activation,and signaling partners of DDR1,its role in different solid tumors,andfinally discusses about designing more DDR1 non-kinase inhibitors as promising therapeutic strategies against DDR1-driven tumors. 展开更多
关键词 discoidin domain receptor 1(DDR1) signaling pathway solid tumors non-kinase inhibitors
下载PDF
非小细胞肺癌组织AIP1、EDIL3表达变化观察
4
作者 马志飞 陈文 +2 位作者 张爱平 沈晓康 郑琳 《山东医药》 CAS 2024年第15期30-34,共5页
目的观察非小细胞肺癌(NSCLC)组织凋亡信号调节激酶1-相互作用蛋白1(AIP1)、表皮生长因子样结构域3(EDIL3)表达变化,分析其与微血管密度(MVD)、临床病理特征及预后的关系,为NSCLC的靶向治疗提供新的干预靶点。方法纳入155例NSCLC患者,... 目的观察非小细胞肺癌(NSCLC)组织凋亡信号调节激酶1-相互作用蛋白1(AIP1)、表皮生长因子样结构域3(EDIL3)表达变化,分析其与微血管密度(MVD)、临床病理特征及预后的关系,为NSCLC的靶向治疗提供新的干预靶点。方法纳入155例NSCLC患者,免疫组织化学法检测癌组织和癌旁组织中AIP1、EDIL3蛋白,Weidner法检测癌组织MVD。比较不同AIP1、EDIL3表达的NSCLC患者MVD值及不同临床病理特征NSCLC患者癌组织AIP1、EDIL3表达水平。Kaplan-Meier生存曲线分析不同AIP1、EDIL3表达的NSCLC患者生存情况,多因素Cox回归分析NSCLC患者预后的影响因素。结果与癌旁组织比较,NSCLC癌组织中EDIL3阳性表达率高、AIP1阳性表达率低(P均<0.05)。不同分化程度、淋巴结转移、肿瘤直径、TNM分期的NSCLC患者癌组织中AIP1、EDIL3蛋白阳性表达率比较,P均<0.05。AIP1阳性表达的NSCLC患者癌组织MVD值低于AIP1阴性表达者(P<0.05),EDIL3阳性表达的NSCLC患者癌组织MVD值高于EDIL3阴性表达者(P<0.05)。EDIL3阳性表达的NSCLC患者3年总生存(OS)率低于EDIL3阴性表达者(P<0.05),AIP1阳性表达的NSCLC患者3年OS率高于AIP1阴性表达者(P<0.05)。淋巴结转移、TNM分期ⅢA期、EDIL3阳性表达是NSCLC患者预后不良的危险因素(P均<0.05),AIP1阳性表达是保护因素(P<0.05)。结论NSCLC癌组织中AIP1阳性表达率降低,EDIL3阳性表达率升高;癌组织中AIP1、EDIL3阳性表达率与MVD、分化程度、淋巴结转移、肿瘤直径、TNM分期有关,是NSCLC预后不良的影响因素。 展开更多
关键词 凋亡信号调节激酶1―相互作用蛋白1 表皮生长因子样结构域3 微血管密度 非小细胞肺癌
下载PDF
DDR2在肺癌中的研究进展
5
作者 李菁霞 金阳 《中国医药指南》 2024年第7期41-44,共4页
肺癌由于恶性程度高、易侵袭转移、治疗效果差、预后差,仍是全球致死率最高的癌症之一,至今还没有非常有效的诊断和治疗方法,阐明肺癌的潜在发病机制对于开发新的有效诊断及预后生物标志物和疗法至关重要。盘状蛋白结构域受体(DDRs),包... 肺癌由于恶性程度高、易侵袭转移、治疗效果差、预后差,仍是全球致死率最高的癌症之一,至今还没有非常有效的诊断和治疗方法,阐明肺癌的潜在发病机制对于开发新的有效诊断及预后生物标志物和疗法至关重要。盘状蛋白结构域受体(DDRs),包括DDR1和DDR2,是跨膜受体酪氨酸激酶超家族的特殊类型。DDR2的异常表达和突变已在多种癌症中报道,参与多种肿瘤生物学行为,因此DDR2是近年来的研究热点之一。本综述总结了目前对DDR2的研究进展,强调了DDR2在肺癌发生和进展中的关键作用以及靶向DDR2在肺癌中的潜在治疗价值。 展开更多
关键词 DDR2 肺癌 靶向治疗 综述
下载PDF
Effect of Bushenhuoxue formula on interleukin-1 beta and discoidin domain receptor 2 levels in a rat model of osteoarthritis 被引量:7
6
作者 Li Nianhu Xia Lei +3 位作者 Yi Sheng Yu Jianhui Zhai Yi Xu Zhanwang 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2015年第2期192-196,共5页
OBJECTIVE:To determine the effects of Bushenhuoxue formula(BHF) on interleukin-1 beta(IL-1β),transforming growth factor beta 1(TGF-β1),discoidin domain receptor 2(DDR2) and matrix metalloproteinase-1(MMP-1) levels i... OBJECTIVE:To determine the effects of Bushenhuoxue formula(BHF) on interleukin-1 beta(IL-1β),transforming growth factor beta 1(TGF-β1),discoidin domain receptor 2(DDR2) and matrix metalloproteinase-1(MMP-1) levels in a rat model of osteoarthritis(OA).METHODS:Sprague-Dawley rats were used to establish an OA model and subjected to various treatments over 6 weeks.Rats were treated with BHF,glucosamine sulfate(G5),or starch as a control.Serum levels of IL-1β and MMP-1 and joint fluid levels of IL-1 β were determined by means of ELISAs.We used immunohistochemistry to determine DDR2 levels in knee cartilage.Gene expression levels of MMP-1 in joint synovial tissue were assessed using reverse transcription polymerase chain reaction assays.RESULTS:Serum IL-1β levels were unchanged throughout the study.Levels of IL-1β in joint fluid and MMP-1 in sera from the BHF- and GS-treated groups were significantly reduced.DDR2 levels in knee cartilage were also significantly reduced in the BHF group.Expression of the MMP-1 gene was significantly reduced by BHF treatment.CONCLUSION:BHF might be beneficial in the inhibition and alleviation of local inflammatory responses and cartilage degeneration in OA. 展开更多
关键词 Osteoarthritis Cytokines discoidin receptor Matrix metalloproteinase 1 Bushenhuoxue formula
原文传递
Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino) quinazolin-6-yl)-N-(3-(trifluoromethyl) phenyl) benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis 被引量:1
7
作者 Qi Wang Bixi Tang +16 位作者 Dandan Sun Ying Dong Yinchun Ji Huanyu Shi Liwei Zhou Yueyue Yang Menglan Luo Qian Tan Lin Chen Yue Dong Cong Li Rongrong Xie Yi Zang Jingkang Shen Bing Xiong Jia Li Danqi Chen 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2022年第4期1943-1962,共20页
Idiopathic pulmonary fibrosis(IPF)is a chronic fatal lung disease with a median survival time of 3–5 years.Inaccurate diagnosis,limited clinical therapy and high mortality together indicate that the development of ef... Idiopathic pulmonary fibrosis(IPF)is a chronic fatal lung disease with a median survival time of 3–5 years.Inaccurate diagnosis,limited clinical therapy and high mortality together indicate that the development of effective therapeutics for IPF is an urgent need.In recent years,it was reported that DDRs are potential targets in anti-fibrosis treatment.Based on previous work we carried out further structure modifications and led to a more selective inhibitor 47 by averting some fibrosis-unrelated kinases,such as RET,AXL and ALK.Extensive profiling of compound 47 has demonstrated that it has potent DDR1/2 inhibitory activities,low toxicity,good pharmacokinetic properties and reliable in vivo anti-fibrosis efficacy.Therefore,we confirmed that discoidin domain receptors are promising drug targets for IPF,and compound 47 would be a promising candidate for further drug development. 展开更多
关键词 Idiopathic pulmonary fibrosis discoidin domain receptor Kinase Inhibitor Docking
原文传递
Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling 被引量:2
8
《Science Foundation in China》 CAS 2016年第4期14-14,共1页
With the support of the National Natural Science Foundation of China and the Ministry of Science and Technology of China,the research teams led by Prof.Gao Hua(高华)from Tongji University,and Prof.Filippo Giancotti at... With the support of the National Natural Science Foundation of China and the Ministry of Science and Technology of China,the research teams led by Prof.Gao Hua(高华)from Tongji University,and Prof.Filippo Giancotti at Memorial Sloan Kettering Cancer Center,reported recently on the mechanism of multiorgan site metastatic creactivation,which was published in Cell(2016,166:47—62). 展开更多
关键词 TM SF DDR JAK Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling
原文传递
氨基酸组成及分子表面属性对胶原与盘状结构域受体DDR2结合能力的影响
9
作者 韩庆秋 寇慧芝 +3 位作者 未本美 许承志 侯袁静 汪海波 《材料导报》 EI CAS CSCD 北大核心 2024年第20期265-271,共7页
本工作利用ELISA实验和细胞黏附实验研究了不同物种来源的胶原样本与盘状结构域受体DDR2及人舌鳞癌细胞CAL-27的结合能力,并进一步探讨了氨基酸组成对胶原与细胞受体DDR2结合能力的影响。结果表明,不同来源的胶原样本与DDR2及CAL-27细... 本工作利用ELISA实验和细胞黏附实验研究了不同物种来源的胶原样本与盘状结构域受体DDR2及人舌鳞癌细胞CAL-27的结合能力,并进一步探讨了氨基酸组成对胶原与细胞受体DDR2结合能力的影响。结果表明,不同来源的胶原样本与DDR2及CAL-27细胞的结合能力存在显著性差异,其中,哺乳动物胶原的结合能力明显大于鱼类胶原,各鱼类胶原之间也存在差异性。通过分析胶原蛋白的氨基酸组成与胶原-受体DDR2结合能力之间的相关性可知,胶原-DDR2结合能力与天冬氨酸、苏氨酸、谷氨酸、甘氨酸、缬氨酸、酸性氨基酸、带电荷极性氨基酸、非极性氨基酸呈负相关,与羟脯氨酸、亚氨基酸、羟基化率(%)、不带电荷极性氨基酸、总极性氨基酸呈正相关(P<0.05)。与此同时,进一步研究了胶原蛋白分子的表面属性对胶原-受体DDR2结合能力的影响。分析表明,较低的Zeta电位绝对值或较高的亲水性均有助于胶原与DDR2的结合。 展开更多
关键词 胶原蛋白 盘状结构域受体DDR2 氨基酸 结合能力
下载PDF
甲状腺癌组织中DCBLD2和MAP4K3的表达及与临床病理特征及预后的关系
10
作者 谈玖婷 傅聿明 +1 位作者 刘婧 张倜然 《现代检验医学杂志》 CAS 2024年第2期34-38,67,共6页
目的 探讨甲状腺癌组织中盘状蛋白含CUB和LCCL结构域2(discoidin CUB and LCCL domain containing 2,DCBLD2)、丝裂原活化蛋白激酶激酶激酶激酶3(mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3)的表达及与临床病理... 目的 探讨甲状腺癌组织中盘状蛋白含CUB和LCCL结构域2(discoidin CUB and LCCL domain containing 2,DCBLD2)、丝裂原活化蛋白激酶激酶激酶激酶3(mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3)的表达及与临床病理特征及预后的关系。方法 选取2016年1月~2020年6月在扬州大学附属兴化市人民医院诊治的92例甲状腺癌患者。采用免疫组织化学(immunohitochemistry,IHC)检测癌组织及癌旁组织中DCBLD2和MAP4K3的表达。比较不同临床病理特征甲状腺癌患者DCBLD2和MAP4K3表达差异。Kaplan-Meier曲线分析不同DCBLD2和MAP4K3表达患者无进展生存预后的差异。多因素COX分析影响甲状腺癌无进展生存预后的危险因素。结果 甲状腺癌组织中DCBLD2(67.39%),MAP4K3(65.22%)阳性率高于癌旁组织(5.43%,6.52%),差异具有统计学意义(χ^(2)=76.262,68.894,均P<0.05)。癌组织中DCBLD2与MAP4K3的表达呈显著正相关(r=0.742,P<0.05)。TNM分期Ⅲ~Ⅳ期、并发淋巴结转移癌组织中DCBLD2的阳性率(87.18%,93.75%)和MAP4K3的阳性率(84.62%,90.63%)分别高于Ⅰ~Ⅱ期(52.83%,50.94%)、无淋巴结转移癌组织(53.33%,51.67%),差异具有统计学意义(χ^(2)=11.230~15.513,均P<0.05)。DCBLD2阳性和阴性组患者三年无进展生存率分别为74.19%(46/62),93.33%(28/30)。MAP4K3阳性和阴性组患者三年无进展生存率分别为75.00%(45/60),90.63%(29/32)。DCBLD2阳性组,MAP4K3阳性组患者三年累积无进展生存率低于DCBLD2阴性组、MAP4K3阴性组,差异具有统计学意义(χ^(2)=4.533,4.138,P=0.033,0.046)。DCBLD2阳性(OR=1.659,P=0.001)、MAP4K3阳性(OR=1.606,P=0.001)、肿瘤TNM分期Ⅲ~Ⅳ期(OR=1.766,P=0.001)和并发淋巴结转移(OR=1.868,P=0.001)是影响甲状腺癌患者无进展生存预后的独立危险因素。结论 甲状腺癌组织中DCBLD2和MAP4K3表达升高,两者均参与甲状腺癌的发生发展,有助于评估甲状腺癌患者的无进展生存预后。 展开更多
关键词 甲状腺癌 盘状蛋白含CUB和LCCL结构域2 丝裂原活化蛋白激酶激酶激酶激酶3 无进展生存预后
下载PDF
抑制盘状结构域受体1蛋白表达对前列腺癌LNCaP细胞恶性生物学行为的影响
11
作者 李沛寰 《肿瘤基础与临床》 2024年第5期497-499,共3页
目的观察短发夹RNA(shRNA)靶向抑制盘状结构域受体1(DDR1)蛋白表达对前列腺癌LNCaP细胞生物学行为的影响。方法将DDR1-shRNA(实验组)与正常对照shRNA(对照组)转染LNCaP细胞,采用Western blot法检测DDR1蛋白的表达,Transwell实验检测细... 目的观察短发夹RNA(shRNA)靶向抑制盘状结构域受体1(DDR1)蛋白表达对前列腺癌LNCaP细胞生物学行为的影响。方法将DDR1-shRNA(实验组)与正常对照shRNA(对照组)转染LNCaP细胞,采用Western blot法检测DDR1蛋白的表达,Transwell实验检测细胞迁移能力,CCK-8法检测细胞增殖能力,Western blot法检测雄激素受体(AR)、B细胞淋巴瘤/白血病-xL(Bcl-xL)、增殖细胞核抗原(PCNA)的表达。结果实验组LNCaP细胞中DDR1蛋白表达水平低于对照组(t=16.293,P<0.001)。抑制DDR1的表达可减弱细胞的迁移能力(t=23.142,P<0.001);降低LNCaP细胞24、48、72和96 h的增殖能力(t=9.363,P<0.001;t=11.261,P<0.001;t=13.562,P<0.001;t=14.332,P<0.001);降低AR、Bcl-xL、PCNA蛋白的表达水平(t=19.131,P<0.001;t=23.192,P<0.001;t=13.235,P<0.001)。结论抑制DDR1蛋白可能通过下调LNCaP细胞中的AR表达,抑制其迁移、增殖能力,作用机制可能与Bcl-xL和PCNA表达降低有关。 展开更多
关键词 前列腺癌 盘状结构域受体1 RNA干扰 雄激素受体
下载PDF
肿瘤细胞外基质及盘状结构域受体1研究进展
12
作者 熊逸潇 杨盛力 张万广 《肿瘤防治研究》 CAS 2023年第8期800-807,共8页
肿瘤细胞外基质(ECM)是肿瘤微环境的重要成分,ECM的多样化和复杂的相互作用构成了肿瘤微环境丰富的异质性,在肿瘤的生长、休眠、耐药和复发转移过程发挥了巨大作用。以DDR1为代表的细胞表面ECM受体,与不同ECM成分通过复杂的相互作用调... 肿瘤细胞外基质(ECM)是肿瘤微环境的重要成分,ECM的多样化和复杂的相互作用构成了肿瘤微环境丰富的异质性,在肿瘤的生长、休眠、耐药和复发转移过程发挥了巨大作用。以DDR1为代表的细胞表面ECM受体,与不同ECM成分通过复杂的相互作用调控肿瘤的发生发展,在肿瘤防治和诊疗领域发挥越来越重要的价值。本文以肿瘤ECM和其受体DDR1为中心,探讨了ECM主要成分、调控方式、细胞受体和信号转导在肿瘤发展过程中的作用及其研究进展。 展开更多
关键词 肿瘤微环境 细胞外基质 盘状结构域受体1
下载PDF
盘状结构域受体1(DDR1):实体肿瘤治疗的新靶点
13
作者 舒航 金腾川 王华 《生物学杂志》 CAS CSCD 北大核心 2023年第2期1-8,共8页
盘状结构域受体家族(discoidin domain receptors,DDRs)成员DDR1广泛表达于人体正常组织,与肿瘤的发生发展密切相关,基于DDR1本身的结构和生物学特点,围绕DDR1在肿瘤研究的进展展开综述,阐述DDR1对肿瘤细胞的增殖生存、迁移侵袭、上皮... 盘状结构域受体家族(discoidin domain receptors,DDRs)成员DDR1广泛表达于人体正常组织,与肿瘤的发生发展密切相关,基于DDR1本身的结构和生物学特点,围绕DDR1在肿瘤研究的进展展开综述,阐述DDR1对肿瘤细胞的增殖生存、迁移侵袭、上皮间质转化和细胞代谢的影响,以及DDR1对肿瘤微环境的重要作用,同时分析以DDR1为靶点的抗肿瘤药物的研究进展,以期为DDR1作为实体肿瘤治疗的新靶点提供理论依据和临床参考。 展开更多
关键词 盘状结构域受体1 肿瘤 信号通路 肿瘤微环境
下载PDF
盘状蛋白结构域受体1在调控恶性肿瘤进展和治疗中的作用
14
作者 李潭 梁新华 《国际口腔医学杂志》 CAS CSCD 2023年第2期230-236,共7页
盘状蛋白结构域受体1 (DDR1)是特殊类型的跨膜受体酪氨酸激酶,在口腔鳞状细胞癌等多种肿瘤中异常表达,并能调控肿瘤进展相关的分子通路。DDR1可参与多种生物学过程,如细胞增殖、分化、迁移、侵袭、休眠和凋亡,还与肿瘤的上皮间充质转化... 盘状蛋白结构域受体1 (DDR1)是特殊类型的跨膜受体酪氨酸激酶,在口腔鳞状细胞癌等多种肿瘤中异常表达,并能调控肿瘤进展相关的分子通路。DDR1可参与多种生物学过程,如细胞增殖、分化、迁移、侵袭、休眠和凋亡,还与肿瘤的上皮间充质转化、免疫排斥、代谢重编程和化疗药物耐药密切相关。部分DDR1抑制剂已在临床研究中显示出抗癌功效。本文回顾了DDR1在肿瘤进展中和DDR1抑制剂在肿瘤治疗中的作用,以期为恶性肿瘤的靶向治疗提供新思路。 展开更多
关键词 盘状蛋白结构域受体1 口腔鳞状细胞癌 恶性肿瘤 抑制剂 靶向治疗
下载PDF
盘状结构域受体1在乳腺癌发生、发展及治疗中的作用
15
作者 伍琦(综述) 王绍波(审校) 《医学研究与战创伤救治》 CAS 北大核心 2023年第4期412-415,共4页
盘状结构域受体1(DDR1)通过与其胶原蛋白配体相互作用,参与调节多种细胞过程,包括增殖、凋亡、侵袭及转移。近年来的研究显示,DDR1不仅在乳腺正常发育过程中起重要作用,还与乳腺癌的进展及预后密切相关。文章主要综述了DDR1在乳腺癌发... 盘状结构域受体1(DDR1)通过与其胶原蛋白配体相互作用,参与调节多种细胞过程,包括增殖、凋亡、侵袭及转移。近年来的研究显示,DDR1不仅在乳腺正常发育过程中起重要作用,还与乳腺癌的进展及预后密切相关。文章主要综述了DDR1在乳腺癌发生、发展以及治疗中的作用,以期为乳腺癌靶向治疗提供理论参考。 展开更多
关键词 盘状结构域受体1 乳腺癌 靶向治疗
下载PDF
下调盘状结构域受体1(DDR1)基因抑制4T-1小鼠乳腺癌细胞的迁移 被引量:3
16
作者 杨婷 张翔 +2 位作者 张晓 杨安钢 张瑞 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2016年第2期217-220,共4页
目的通过短发夹RNA(shRNA)下调小鼠盘状结构域受体1(DDR1)基因的表达,并观察DDR1下调后对4T-1小鼠乳腺癌细胞迁移的影响。方法针对鼠的DDR1基因设计并合成2对shRNA干涉序列连入p LKO.1慢病毒表达载体中。测序正确后利用慢病毒包装系统... 目的通过短发夹RNA(shRNA)下调小鼠盘状结构域受体1(DDR1)基因的表达,并观察DDR1下调后对4T-1小鼠乳腺癌细胞迁移的影响。方法针对鼠的DDR1基因设计并合成2对shRNA干涉序列连入p LKO.1慢病毒表达载体中。测序正确后利用慢病毒包装系统包装表达shRNA的重组病毒,用获得的病毒感染4T-1细胞,用嘌呤霉素(puromycin)筛选并建立稳定细胞系。采用实时定量PCR和Western blot法确定DDR1基因的下调效果。利用TranswellTM小室迁移实验观察DDR1下调后的4T-1细胞迁移能力的变化。结果经测序鉴定后,成功构建了慢病毒p LKO-sh DDR1-1、p LKO-sh DDR1-2以及阴性对照慢病毒p LKO-sh NT。用重组病毒感染4T-1细胞,建立稳定细胞系,实时定量PCR和Western blot法结果表明DDR1基因的明显下调。TranswellTM小室实验显示,与感染p LKO-sh NT的对照细胞相比,感染p LKO-sh DDR1-1和p LKO-sh DDR1-2的细胞迁移能力明显降低。结论下调DDR1基因的表达可以抑制4T-1乳腺癌细胞的迁移。 展开更多
关键词 盘状结构域受体1(discoidin DOMAIN RECEPTOR 1) 慢病毒载体 迁移 4T-1细胞
原文传递
MMP-1、13 mRNA和DDR2表达与关节软骨退变的关系 被引量:27
17
作者 张超 王旭 +1 位作者 姜建元 黄煌渊 《复旦学报(医学版)》 CAS CSCD 北大核心 2007年第1期126-128,共3页
目的探讨关节软骨基质金属蛋白酶(matrix metalloproteinase,MMPs)-1、13mRNA及盘状结构域受体(discoidin domain receptor,DDR2)三者与关节软骨退变的关系。方法对58例关节软骨标本应用反转录-多聚酶链反应法(RT-PCR)测定MMP-1、13mRN... 目的探讨关节软骨基质金属蛋白酶(matrix metalloproteinase,MMPs)-1、13mRNA及盘状结构域受体(discoidin domain receptor,DDR2)三者与关节软骨退变的关系。方法对58例关节软骨标本应用反转录-多聚酶链反应法(RT-PCR)测定MMP-1、13mRNA的表达,免疫组化法显色DDR2表达,进行图像分析研究。结果在轻度退变关节软骨中MMP-1、13呈低表达,在中重度退变软骨中MMP-1、13表达显著增高,在重度退变软骨中MMP-1,13有相对的下降,DDR2表达也呈现出与MMP-1、13相同的表达特点。结论MMP-1、13的过表达导致软骨Ⅱ型胶原的降解是软骨退变的重要原因,Ⅱ型胶原降解片段诱导DDR2表达增高进一步介导MMP-1、13的表达形成一个放大效应而加速了关节软骨退变。 展开更多
关键词 骨关节炎 基质金属蛋白酶 盘状结构域受体
下载PDF
盘状结构域受体1的研究进展 被引量:8
18
作者 谢瑞霞 王小英 +1 位作者 张建刚 张德奎 《基础医学与临床》 CSCD 北大核心 2014年第4期555-558,共4页
盘状结构域受体1(DDR1)是近年来发现的一利新型受体型蛋白酪氨酸激酶(RTK),能与多种胶原蛋白特异性结合并被激活,活化一系列细胞内外信号传导,参与多种疾病过程,如肿瘤的发生发展、炎性反应和纤维化的发生,进展等。
关键词 盘状结构域受体1 受体型蛋白酪氨酸激酶 肿瘤 炎性反应 纤维化
下载PDF
DDR2与MMP2在酒精性肝病肝窦毛细血管化中的协同表达 被引量:3
19
作者 阎明 刘慧敏 +2 位作者 张喜红 张玉泉 罗争 《中国病理生理杂志》 CAS CSCD 北大核心 2010年第8期1515-1520,共6页
目的:探讨盘状区域受体2(DDR2)与基质金属蛋白酶(MMP2)在酒精性肝纤维化大鼠肝窦毛细血管化病理进程中的表达及可能发挥的作用。方法:橄榄油拌平衡饲料喂养大鼠的基础上给予60%(V/V)白酒胃内灌注制备酒精性肝纤维化模型,分别于4周、8周... 目的:探讨盘状区域受体2(DDR2)与基质金属蛋白酶(MMP2)在酒精性肝纤维化大鼠肝窦毛细血管化病理进程中的表达及可能发挥的作用。方法:橄榄油拌平衡饲料喂养大鼠的基础上给予60%(V/V)白酒胃内灌注制备酒精性肝纤维化模型,分别于4周、8周、12周和16周末观察肝组织网状纤维染色、免疫组化染色(Ⅰ、Ⅳ型胶原及层黏连蛋白),荧光定量-PCR和Western blotting检测肝组织DDR2及MMP2基因和蛋白表达并与肝窦毛细血管化各项评价指标进行相关性分析。结果:大鼠白酒灌胃4周出现肝脏脂肪变性,随灌胃时间延长逐渐加重为肝脏坏死、炎症及纤维化。酒精性肝病模型组大鼠DDR2 mRNA和蛋白表达量显著高于对照组,且随造模时间延长表达增加(P<0.01)。MMP2 mRNA和蛋白表达自造模4周开始升高,于12周达峰值,造模16周下降,各模型组MMP2 mRNA和蛋白表达较正常对照组明显升高(P<0.05)。相关性分析显示DDR2与MMP2、网状纤维、Ⅰ、Ⅳ型胶原及层黏连蛋白表达均呈显著正相关。结论:在酒精性肝病肝窦毛细血管化病程中DDR2表达呈时间依赖性,其可能通过效应蛋白MMP2在肝窦毛细血管化的发生和进展中发挥重要作用。 展开更多
关键词 肝硬化 酒精性 肝窦毛细血管化 受体 盘状区域 基质金属蛋白酶2
下载PDF
High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients 被引量:7
20
作者 Jian-Cong Sun,Xiao-Ting Liang,Ke Pan,Hui Wang,Jing-Jing Zhao,Jian-Jun Li,Hai-Qing Ma,Yi-Bing Chen,Jian-Chuan Xia,State Key Laboratory of Oncology in South China,Cancer Center,Sun Yat-Sen University,Guangzhou 510060,Guangdong Province,China 《World Journal of Gastroenterology》 SCIE CAS CSCD 2010年第36期4611-4615,共5页
AIM:To determine the role of epidermal growth factor-like repeats and discoidin I-like domains 3(EDIL3)in pathogenesis of hepatocellular carcinoma(HCC)by investigating the EDIL3 expression in HCC and its prognostic va... AIM:To determine the role of epidermal growth factor-like repeats and discoidin I-like domains 3(EDIL3)in pathogenesis of hepatocellular carcinoma(HCC)by investigating the EDIL3 expression in HCC and its prognostic value for HCC.METHODS:EDIL3 expression was detected in 101 HCC surgical tissue samples with immunohistochemistry method,and its relation with clinicopathologic features and prognosis of HCC patients was analyzed.RESULTS:EDIL3 was highly expressed in 48.5%of the HCC patients.Although the EDIL3 expression level did not correlate with any clinicopathological parameters,KaplanMeier survival analysis showed that high expression level of EDIL3 resulted in a significantly poor prognosis of HCC patients(log-rank test,P=0.010).Multivariate Cox's analysis showed that the EDIL3 expression level was a significant and independent prognostic parameter for the overall survival rate of HCC patients(hazard ratio=1.978,95%confidence interval =1.139-3.435,P=0.015).CONCLUSION:High expression level of EDIL3 pre-dicts poor prognosis of HCC patients.EDIL3 may be a potential target of antiangiogenic therapy for HCC. 展开更多
关键词 EPIDERMAL growth factor-like REPEATS and discoidin I-like DOMAINS 3 HEPATOCELLULAR carcinoma Prognosis Angiogenesis
下载PDF
上一页 1 2 5 下一页 到第
使用帮助 返回顶部